Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds (Q112636832)
Jump to navigation
Jump to search
scientific article published on 02 May 2022
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds |
scientific article published on 02 May 2022 |
Statements
Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds (English)
Thomas Wilke
Nils Picker
Anna Stürmlinger
Barthold Deiters
Axel Dittmar
Jens Aberle
Maximilian Gabler